Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC) and explore the efficacy predictors, we perform a multi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cell reports. Medicine 2022-11, Vol.3 (11), p.100785, Article 100785
Hauptverfasser:	Hu, Jiao, Chen, Jinbo, Ou, Zhenyu, Chen, Haige, Liu, Zheng, Chen, Minfeng, Zhang, Ruiyun, Yu, Anze, Cao, Rui, Zhang, Enchong, Guo, Xi, Peng, Bo, Deng, Dingshan, Cheng, Chunliang, Liu, Jinhui, Li, Huihuang, Zou, Yihua, Deng, Ruoping, Qin, Gang, Li, Wenze, Wang, Lue, Chen, Tao, Pei, Xiaming, Gong, Guanghui, Tang, Jiansheng, Othmane, Belaydi, Cai, Zhiyong, Zhang, Chunyu, Liu, Zhi, Zu, Xiongbing
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Cohort Studies Humans Immunotherapy Muscles - pathology Neoadjuvant Therapy Neoplasm Invasiveness Retrospective Studies Urinary Bladder Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!